Toru Baba
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Toru Baba has a total of 172 co-authors. Here are the top co-authors by number of shared publications:
Atsushi Takeda
Department of Neurology, National Hospital Organization Sendai-Nishitaga Hospital, Sendai, Japan
23 shared publicationsEtsuro Mori
18 shared publicationsAkio Kikuchi
Division of Neurology, Department of Neuroscience & Sensory Organs, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan
17 shared publicationsTakafumi Hasegawa
Department of Neurology, National Hospital Organization Sendai-Nishitaga Hospital, Sendai, Japan
17 shared publicationsMasashi Aoki
Division of Neurology, Department of Neuroscience & Sensory Organs, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan
16 shared publicationsNaoto Sugeno
Division of Neurology, Department of Neuroscience & Sensory Organs, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan
16 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by Elsevier in SSRN Electronic Journal
A Serum Neurofilament Light-Based Risk Score Predicts Cognitive Decline in Early Parkinson’s Disease: A Longitudinal Parkinson’s Progression Markers Initiative Study
Background: The progression of Parkinson’s disease (PD), particularly cognitive decline, is substantially heterogeneous. Serum neurofilament light chain (NfL) is a useful biomarker of neurodegeneration, and PD patients with high serum NfL levels are more likely to develop dementia.Objective: We investigated whether a composite risk score (sNfL-Risk score) that combines serum NfL with age, cognition, motor severity, and RBD-related symptoms can predict cognitive decline in PD.Methods: We conducted a prospective cohort study using datasets from the Parkinson’s Progression Markers Initiative (PPMI). The sNfL-Risk score was constructed by integrating scores for serum NfL, age, MoCA, UPDRS part III, and RBDSQ. Associations between the sNfL-Risk score and cognitive decline were evaluated using logistic regression and net reclassification improvement (NRI) analyses.Results: A strong association was observed between higher sNfL-Risk scores and an increased risk of cognitive decline at 5 years. Each 1-point increase in the sNfL-Risk score was associated with 2.65-fold greater odds of cognitive decline at 5 years (95% Confidence interval (CI) 2.12–3.32; p < 0.0001). The higher the risk score was, the more significantly the probability of cognitive decline within 5 years increased, exceeding 48% in patients with scores ≥3. Compared with NfL alone, the sNfL-Risk score performed better in predicting cognitive decline (AUC 0.8 vs. 0.684; p < 0.0001) and demonstrated superiority in risk stratification (categorical NRI 0.255; p = 0.006).Conclusions: The sNfL-Risk score may be useful for stratifying patients at risk of PD-related cognitive decline and may contribute to the development of personalized management strategies.
- 25 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessA Serum Neurofilament Light-Based Risk Score Predicts Cognitive Decline in Early Parkinson’s Disease: A Longitudinal Parkinson’s Progression Markers Initiative Study
Background: The progression of Parkinson’s disease (PD), particularly cognitive decline, is substantially heterogeneous. Serum neurofilament light chain (NfL) is a useful biomarker of neurodegeneration, and PD patients with high serum NfL levels are more likely to develop dementia.Objective: We investigated whether a composite risk score (sNfL-Risk score) that combines serum NfL with age, cognition, motor severity, and RBD-related symptoms can predict cognitive decline in PD.Methods: We conducted a prospective cohort study using datasets from the Parkinson’s Progression Markers Initiative (PPMI). The sNfL-Risk score was constructed by integrating scores for serum NfL, age, MoCA, UPDRS part III, and RBDSQ. Associations between the sNfL-Risk score and cognitive decline were evaluated using logistic regression and net reclassification improvement (NRI) analyses.Results: A strong association was observed between higher sNfL-Risk scores and an increased risk of cognitive decline at 5 years. Each 1-point increase in the sNfL-Risk score was associated with 2.65-fold greater odds of cognitive decline at 5 years (95% Confidence interval (CI) 2.12–3.32; p < 0.0001). The higher the risk score was, the more significantly the probability of cognitive decline within 5 years increased, exceeding 48% in patients with scores ≥3. Compared with NfL alone, the sNfL-Risk score performed better in predicting cognitive decline (AUC 0.8 vs. 0.684; p < 0.0001) and demonstrated superiority in risk stratification (categorical NRI 0.255; p = 0.006).Conclusions: The sNfL-Risk score may be useful for stratifying patients at risk of PD-related cognitive decline and may contribute to the development of personalized management strategies.
- Open Access
- 4 September 2026
- Published by Springer Nature in Neurology and Therapy
- Vol. 15 (5) , 2807-2821
Characteristics and Hospitalization Details of Patients with Advanced Parkinson’s Disease Receiving Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa: Real-World First-Year Descriptive Study from Japan
Introduction The real-world characteristics of patients with advanced Parkinson’s disease (PD) who receive foslevodopa/foscarbidopa (LDp/CDp) continuous subcutaneous infusion therapy (CSCI) remain poorly understood. This study aimed to describe the characteristics and hospitalization details of patients with advanced PD hospitalized for LDp/CDp CSCI in Japan. Methods This study was a retrospective descriptive analysis conducted using a hospital-based database provided by Medical Data Vision, Co. Ltd. Patients with advanced PD who underwent LDp/CDp CSCI during hospitalization between July 2023 and June 2024 were enrolled. The index date was defined as the date of the first LDp/CDp prescription. Baseline patient characteristics, levodopa-equivalent dose (LED), number of pills/transdermal patches, medication classes for concomitant PD medications, and non-motor symptom medications assessed within 4 weeks prior to and including the index date, along with hospitalization details, were collected. Results We enrolled 96 patients with a mean age of 65.6 years [standard deviation (SD), 10.2], of whom 58 (60.4%) were female. The median Barthel Index was 90.0 [interquartile range (IQR): 44.2], and the hospitalization duration was 15.0 days (IQR: 9.0). Eighteen patients (18.8%) discontinued LDp/CDp CSCI during hospitalization. The mean LED of any PD medications prior to LDp/CDp CSCI initiation, the mean number of PD medication classes, and the daily pill/transdermal patch count for PD medications were 1,111.0 mg/day (SD 575.7), 3.9 (SD 1.3), and 10.6 (SD 5.0), respectively. Except for levodopa (L-Dopa), dopamine agonists (78.1%) were the most commonly used concomitant PD medications. Conclusions In real-world clinical practice in Japan, patients with LDp/CDp CSCI tend to be younger and have preserved activities of daily living. Our results implied that patients are often managed with multiple concomitant PD medications rather than with L-Dopa dose titration prior to initiation. Further research is warranted to maximize the benefits of LDp/CDp CSCI and assess its real-world impact on pill burden.
- 4 September 2026
- Published by Springer Nature in Neurology and Therapy
- Vol. 15 (5) , 2807-2821
Open AccessCharacteristics and Hospitalization Details of Patients with Advanced Parkinson’s Disease Receiving Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa: Real-World First-Year Descriptive Study from Japan
Introduction The real-world characteristics of patients with advanced Parkinson’s disease (PD) who receive foslevodopa/foscarbidopa (LDp/CDp) continuous subcutaneous infusion therapy (CSCI) remain poorly understood. This study aimed to describe the characteristics and hospitalization details of patients with advanced PD hospitalized for LDp/CDp CSCI in Japan. Methods This study was a retrospective descriptive analysis conducted using a hospital-based database provided by Medical Data Vision, Co. Ltd. Patients with advanced PD who underwent LDp/CDp CSCI during hospitalization between July 2023 and June 2024 were enrolled. The index date was defined as the date of the first LDp/CDp prescription. Baseline patient characteristics, levodopa-equivalent dose (LED), number of pills/transdermal patches, medication classes for concomitant PD medications, and non-motor symptom medications assessed within 4 weeks prior to and including the index date, along with hospitalization details, were collected. Results We enrolled 96 patients with a mean age of 65.6 years [standard deviation (SD), 10.2], of whom 58 (60.4%) were female. The median Barthel Index was 90.0 [interquartile range (IQR): 44.2], and the hospitalization duration was 15.0 days (IQR: 9.0). Eighteen patients (18.8%) discontinued LDp/CDp CSCI during hospitalization. The mean LED of any PD medications prior to LDp/CDp CSCI initiation, the mean number of PD medication classes, and the daily pill/transdermal patch count for PD medications were 1,111.0 mg/day (SD 575.7), 3.9 (SD 1.3), and 10.6 (SD 5.0), respectively. Except for levodopa (L-Dopa), dopamine agonists (78.1%) were the most commonly used concomitant PD medications. Conclusions In real-world clinical practice in Japan, patients with LDp/CDp CSCI tend to be younger and have preserved activities of daily living. Our results implied that patients are often managed with multiple concomitant PD medications rather than with L-Dopa dose titration prior to initiation. Further research is warranted to maximize the benefits of LDp/CDp CSCI and assess its real-world impact on pill burden.
- Open Access
- 7 January 2026
- Published by Elsevier in Clinical Parkinsonism & Related Disorders
- Vol. 14
Temporal patterns of motor and nonmotor symptom emergence in Parkinson’s disease: a cluster analysis
- 7 January 2026
- Published by Elsevier in Clinical Parkinsonism & Related Disorders
- Vol. 14
Open AccessTemporal patterns of motor and nonmotor symptom emergence in Parkinson’s disease: a cluster analysis
- Open Access
- 3 July 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 257, 109040
System-wise balance evaluation and its association with structural brain changes in Parkinson’s disease
- 3 July 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 257, 109040
Open AccessSystem-wise balance evaluation and its association with structural brain changes in Parkinson’s disease
- Open Access
- 5 July 2024
- Published by Elsevier in Brain Disorders
- Vol. 15
Blake's pouch cyst-like imaging abnormalities in idiopathic normal pressure hydrocephalus
- 5 July 2024
- Published by Elsevier in Brain Disorders
- Vol. 15
Open AccessBlake's pouch cyst-like imaging abnormalities in idiopathic normal pressure hydrocephalus
- Open Access
- 30 September 2023
- Published by Japan Society for Higher Brain Dysfunction in Higher Brain Function Research
- Vol. 43 (3) , 207-211
嗅覚検査と脳画像でせまるパーキンソン病の認知機能障害
パーキンソン病 (PD) では寡動, 筋強剛, 静止時振戦などの運動症状以外にも嗅覚障害, レム睡眠行動障害, 自律神経障害, 認知機能障害および精神症状など多彩な非運動症状を認めることが知られている。認知機能障害は, 重症化すると認知症にもつながる臨床的にきわめて重要な非運動症状であり, 患者・家族の QOL や予後にも大きく影響することから, 初期からの適切な評価, 治療介入が望まれている。 しかし, 患者によって認知機能障害の程度やパターン, 悪化速度が大きく異なるため, 現在のところ PD の認知機能低下を初期から正確に予測するのは困難だが, 最近では非運動症状を手がかりに PD の認知機能低下を予測しようとする取り組みが盛んになっている。本稿では PD の代表的な非運動症状である嗅覚障害から認知機能障害の早期発見, 治療介入にどう結び付けていくか, 我々の研究結果も交えて紹介する。
- 30 September 2023
- Published by Japan Society for Higher Brain Dysfunction in Higher Brain Function Research
- Vol. 43 (3) , 207-211
Open Access嗅覚検査と脳画像でせまるパーキンソン病の認知機能障害
パーキンソン病 (PD) では寡動, 筋強剛, 静止時振戦などの運動症状以外にも嗅覚障害, レム睡眠行動障害, 自律神経障害, 認知機能障害および精神症状など多彩な非運動症状を認めることが知られている。認知機能障害は, 重症化すると認知症にもつながる臨床的にきわめて重要な非運動症状であり, 患者・家族の QOL や予後にも大きく影響することから, 初期からの適切な評価, 治療介入が望まれている。 しかし, 患者によって認知機能障害の程度やパターン, 悪化速度が大きく異なるため, 現在のところ PD の認知機能低下を初期から正確に予測するのは困難だが, 最近では非運動症状を手がかりに PD の認知機能低下を予測しようとする取り組みが盛んになっている。本稿では PD の代表的な非運動症状である嗅覚障害から認知機能障害の早期発見, 治療介入にどう結び付けていくか, 我々の研究結果も交えて紹介する。
- 13 August 2022
- Published by Elsevier in Auris Nasus Larynx
- Vol. 50 (2) , 247-253
Bedside evaluation of swallowing function to predict aspiration pneumonia in Duchenne muscular dystrophy
- 13 August 2022
- Published by Elsevier in Auris Nasus Larynx
- Vol. 50 (2) , 247-253
Bedside evaluation of swallowing function to predict aspiration pneumonia in Duchenne muscular dystrophy
- 27 June 2022
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 9 (6) , 852-853
Reply: Ventriculomegaly in Prodromal Idiopathic Normal Pressure Hydrocephalus?
- 27 June 2022
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 9 (6) , 852-853
Reply: Ventriculomegaly in Prodromal Idiopathic Normal Pressure Hydrocephalus?
- 28 July 2021
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 8 (7) , 1150-1152
Ventriculomegaly Is the First Brain Morphological Change in Prodromal Idiopathic Normal Pressure Hydrocephalus
- 28 July 2021
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 8 (7) , 1150-1152
Ventriculomegaly Is the First Brain Morphological Change in Prodromal Idiopathic Normal Pressure Hydrocephalus
- 7 June 2020
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 8 (6) , 351-355
Cognitive impairment and its association with cholinergic dysfunction in Parkinson’s disease
Cognitive impairment is an important nonmotor symptom in Parkinson's disease (PD). In recent years, much research has focused on cholinergic dysfunction as a principal cause of early cognitive decline in PD. Cholinergic dysfunction is common and produces characteristic impairments in multiple cognitive domains; furthermore, it is associated with future dementia in PD. Recently, it has become possible to measure the volume of the human cholinergic nucleus, and this technique has been increasingly applied in PD research. Here, we review the current state of knowledge on cognitive dysfunction and neuroimaging studies, with particular focus on atrophy of the cholinergic nucleus in PD.
- 7 June 2020
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 8 (6) , 351-355
Cognitive impairment and its association with cholinergic dysfunction in Parkinson’s disease
Cognitive impairment is an important nonmotor symptom in Parkinson's disease (PD). In recent years, much research has focused on cholinergic dysfunction as a principal cause of early cognitive decline in PD. Cholinergic dysfunction is common and produces characteristic impairments in multiple cognitive domains; furthermore, it is associated with future dementia in PD. Recently, it has become possible to measure the volume of the human cholinergic nucleus, and this technique has been increasingly applied in PD research. Here, we review the current state of knowledge on cognitive dysfunction and neuroimaging studies, with particular focus on atrophy of the cholinergic nucleus in PD.